Skip to main content
What types of page to search?

Popular pages: Undergraduate Postgraduate PhD Accommodation Research International students

Alternatively use our A-Z index.

European Novel Drug Research to Address Microbial Infections and Drug Resistance (END2AMR)

European Novel Drug Research to Address Microbial Infections and Drug Resistance (END2AMR) is public/private consortium research initiative, aiming to tackle some of the most difficult-to-treat bacterial infections.

Led by Lygature, END2AMR gathers a range of different teams, including leading academic groups, research institutes, SMEs and industry partners.

The diverse expertise of these teams spans drug discovery, microbiology, medicinal chemistry, phage-derived proteins, protein degradation technologies, Nanofitin delivery systems, long-acting therapeutics, in vitro and in vivo infectious disease models, and tuberculosis drug development.

Project overview

The END2AMR partnership is working together to develop a new generation of antibacterial modalities and delivery technologies.

Antimicrobial resistance (AMR) is one of the top health threats in Europe, leading to many deaths and strains on health systems across the continent. Through a coordinated research effort, END2AMR plans to deliver new scientific strategies as current systems are not meeting patient needs.

“The consortium will focus on chronic and drug-resistant infections caused by Gram-negative bacteria and Mycobacterium tuberculosis, which are responsible for significant global morbidity and mortality.” – Lygature

END2AMR’s five-year plan is set to:

  • Develop and evaluate diverse novel antibacterial modalities with new modes of action, which will include PROTACs, small molecules, and phage lysins
  • Create innovative delivery systems, including Nanofitin-based technologies and long-acting therapeutic formulations
  • Build a versatile “toolbox” that is scalable and can be applied to a wide range of pathogens and clinical contexts
  • Strengthen Europe’s preparedness for future infectious disease outbreaks by generating adaptable platforms and technologies.

CELT Global Health's objectives

CELT Global Health provide expertise in pharmacology and materials chemistry to the consortium. Our experience of translational collaborative projects will enable the END2AMR consortium to prepare for future long-acting medicines.

Our input aims to facilitate a new generation of long-acting medicines targeting the growing global challenge of antimicrobial resistance. Long-acting drug delivery is proving to be transformational for control of other devastating diseases. We will explore if similar approaches to mitigate challenges, such as patient adherence, can provide solutions in the face of AMR’s growing public health challenge.

Awarding body

Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101253465.

Consortium partners

The END2AMR consortium brings together 12 partners from across Europe and the United States, representing expertise from academia, research institutes, SMEs, and industry:

  1. Lygature (Coordinator)
  2. GSK (Industry Lead)
  3. University of Dundee (Scientific Lead)
  4. University of Liverpool / CELT Global Health
  5. Obulytix
  6. University of Copenhagen
  7. CEA
  8. Quadram Institute
  9. Francis Crick Institute
  10. University of Manchester
  11. Affilogic
  12. TB Alliance